Dr. Nipun Verma
@drnipunverma.bsky.social
Clinician Hepatologist dedicated to patient care, teaching and research..
💡 Should NAD patients be prioritized for earlier intervention? Could targeting necroptosis & pyroptosis prevent disease progression?
March 7, 2025 at 4:09 PM
💡 Should NAD patients be prioritized for earlier intervention? Could targeting necroptosis & pyroptosis prevent disease progression?
🔬 Key findings:
✔️ NAD patients have increased cell death (RIPK3, Gasdermin-D) but no systemic inflammation
✔️ 55% progress to AD within 12 months—leading to worse survival
✔️ Low IGF-1, high bilirubin, severe ascites predict progression @easlnews.bsky.social
✔️ NAD patients have increased cell death (RIPK3, Gasdermin-D) but no systemic inflammation
✔️ 55% progress to AD within 12 months—leading to worse survival
✔️ Low IGF-1, high bilirubin, severe ascites predict progression @easlnews.bsky.social
March 7, 2025 at 4:09 PM
🔬 Key findings:
✔️ NAD patients have increased cell death (RIPK3, Gasdermin-D) but no systemic inflammation
✔️ 55% progress to AD within 12 months—leading to worse survival
✔️ Low IGF-1, high bilirubin, severe ascites predict progression @easlnews.bsky.social
✔️ NAD patients have increased cell death (RIPK3, Gasdermin-D) but no systemic inflammation
✔️ 55% progress to AD within 12 months—leading to worse survival
✔️ Low IGF-1, high bilirubin, severe ascites predict progression @easlnews.bsky.social
🚨 New Insights in Cirrhosis! 🚨
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
March 7, 2025 at 4:09 PM
🚨 New Insights in Cirrhosis! 🚨
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
🚀 AI & ML are transforming liver disease care!
🔬our @akashroyy.bsky.social review explores how machine learning enhances diagnosis & outcome prediction in alcohol-related & metabolic dysfunction-associated steatotic liver diseases (MASLD). 🔍
🔗 oaepublish.com/articles/mtod.…#AIA#Liverer
🔬our @akashroyy.bsky.social review explores how machine learning enhances diagnosis & outcome prediction in alcohol-related & metabolic dysfunction-associated steatotic liver diseases (MASLD). 🔍
🔗 oaepublish.com/articles/mtod.…#AIA#Liverer
February 25, 2025 at 4:47 PM
🚀 AI & ML are transforming liver disease care!
🔬our @akashroyy.bsky.social review explores how machine learning enhances diagnosis & outcome prediction in alcohol-related & metabolic dysfunction-associated steatotic liver diseases (MASLD). 🔍
🔗 oaepublish.com/articles/mtod.…#AIA#Liverer
🔬our @akashroyy.bsky.social review explores how machine learning enhances diagnosis & outcome prediction in alcohol-related & metabolic dysfunction-associated steatotic liver diseases (MASLD). 🔍
🔗 oaepublish.com/articles/mtod.…#AIA#Liverer